DOCSLIB.ORG

Biocatalysis and Process Integration in the Synthesis of Semi-Synthetic Antibiotics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Biocatalysis and Process Integration in the Synthesis of Semi-Synthetic Antibiotics BIOTECHNOLOGY FOR INDUSTRIAL PRODUCTION OF FINE CHEMICALS 431 C'HIMIA 50(1996) Nr. 9 (SCpIC11l~CI') nates of the native wild-type apoenzyme cal applications from the development of menea, S.D. Varfolomeyev, l.R. Wild, Bi- (fromH. Holden, U. Wisconsin) and mod- transgenic soil fungi and plants to whole osensors and Bioelectronics] 996, in press. eling of important features at the active cell hydrolysis in slurry-bed bioreacter [4] K. Lai, N.J. Stolowich, Arch. Biochem. Biophys. 1995,318,59. site suggest critical attributes that can be systems to air stream purging and devel- [5] F. Yang, J.R. Wild, A.L. Russell, Biotecll- further modified to continue the rational opment of neurotoxin-specific bioreac- nol. Prog. 1995, 11, 71. design of this enzyme for bioremediation tors (see references) is quite pronounced. [6] F.c.G. Hoskin, J.E. Walker, W-D. Dett- of pesticide contaminants and CW A stock- bam,J.R. Wild, Biochem. Pharnwcol.1995, piles. OPH is one of the few enzymes 49, 711. which has been shown to be capable of [7] lE. Kolakowski, J.J. DeFrank, K. Lai, l.R. [I) B. Xu, l.R. Wild, C.M. Kenerley, J. Fer- Wild, 1996, submitted for publication. hydrolyzing the P-S bond of various OP mentation and Bioengineering 1996, 81, [8] KJ. Dave, L. Phillips, VA Luckow, J.R. pesticides; however, it possesses a wide 473. Wild, Biotech. and Appl. Biochem. ]994, range of catalytic rates (0.0067-167 S-I). [2] J.K. Grimsley, V.K. Ratogi, J.R. Wild, 19,271. Nonetheless, it has been possible to en- 'Biological Systems for the Detoxification [9] K. Lai, K.I. Dave, J.R. Wild, J. Bioi. Chem. hance the unique P-S bond hydrolysis of of Organophosphorus Neurotoxins: Poten- 1994,269, 16579. this enzyme by selecting specific changes tial for Environmental Remediation Appli- [10] L. Pei, G. Omburo, W.O. McGuinn,. I. cations', in 'Bioremediation: Principles and in the amino acids bordering the active Petrikovics, K.J. Dave, F.M. Raushel, J.R. Practice', Eds. S.K. Sikdar and R.L. Irvine, Wild, J.R. DeLoach, l.L. Way, Toxicol. site. Thus, it appears that the capacity for Technomic Publishing Co. Inc., 1996, in Appl. Pharmacal. ]994, 124,296. further improvement is remarkable, and press. [II] K.I. Dave, C.E. Miller, J.R. Wild, Clzem.- the opportunity for a variety ofbiotechni- [3] E.!. Rainina, A.L. Simonian, E.N. EIre- Bioi. Interact. 1993, 87, 55. Chimia 50 (1996) 431-432 The Chemferm Process © Neue Schweizerisclze Cizemische Gesellschaft ISSN 0009-4293 In the Chemferm process (Fig.) only six steps are needed, whereby biocatalysis is involved in three of them [4]; a major Biocatalysis and Process improvement through the eyes of the or- ganicchemist [5]. However, when itcomes Integration in the Synthesis of to the design of the production plant for the final coupling step, the engineers are Semi-synthetic Antibiotics faced with an equilibrium process requir- ing recycle of starting materials and han- dling of many solids: Aile Bruggink* - crystallization and isolation of the de- sired cefalexin, - crystallization and recovery of excess Introduction - the low entry barrier, i.e. low invest- 7-ADCA (= 7-aminodeacetoxycepha- ments, for new technologies in this losporanic acid), The fine chemical industry is one of small scale industry, facilitated by the - crystallization and isolation of phe- the industry segments where the impact of fact that fine chemical companies be- nylglycine from undesired hydrolysis biocatalysis is felt most profoundly. Pos- come increasingly part oflarger indus- of both end product and side-chain sible explanations are [1][2]: trial conglomerates. precursor. - the need to replace traditional, stoichio- So far, in our developments at Chem- metric processes in order to improve ferm, the environment has been the main the product to waste ratio, Synthesis of Semi-synthetic Antibiotics winner. Only aqueous waste streams con- the failure to translate chemocatalytic taining some simple inorganic salts are processes from petrochemicals to fine The industrial production of semi-syn- produced, whereas the traditional process chemicals, thetic antibiotics, with a history of some releases methylene chloride and other sol- - the ready acceptance of enzymes by 30 years, is an outstanding example of the vents and needs stoichiometric amounts the organic chemist as part of his tool- development of biocatalysis. Cefalexin, of silylating agents, Dane-salt-protected box, whereas organic chemistry is still with an annual consumption of almost side chains and acylating promotors (such the dominating discipline in fine chem- 2000 t, the largest cephalosporin on the as pivaloyl chloride) which all end up as ical industry [3], world market, serves as a useful illustra- waste. tion. The original synthesis (see Fig.) start- ing from benzaldehyde and fermentation of penicillin G was a ten-step process The NOVO Process *Correspondence: Prof. Dr. A. Brugginka)b) employing stoichiometric chemistry only ") Chernferm. Industrial Pharmaceuticals and causing a waste stream of 30-40 kg An alternative process was developed P.O. Box 3933 per kg of end product. Often 4-6 different by NOVO, acquired and further improved NL-4800 OX Breda companies were involved to serve the chain by Chemferm. Using /3-naphthol as com- b) University of Nijmegen Department of Organic Chemistry from basic raw materials to bulk drug; plexing agent, which surprisingly is com- Toernooiveld nowadays one or two companies cover the patible with the enzymatic condensation NL-6525 ED Nijmegen full production column. conditions, an almost quantitative yield of BIOTECHNOLOGY FOR INDUSTRIAL PRODUCTION OF FINE CHEMICALS 432 CHIMIA 50 (1996) Nr. 9 (Septemher) NEW ROUTE TO CEFALEXIN WITH FOUR FEWER STEPS AND MORE ENZYMATIC REACTIONS FORMER ROUTE NEW ROUTE [BENZALDEHYDE ~ PENICI~LUM---· ~ BENZALDEHYDE IPENI~.ILLlU~_- _ J STRECKER SYNTHESIS FERMENTATION FERMENTATION * CHEMICAL * BIOCA TAL YTIC STRECKER SYNTHESIS * BIOCATALYTIC * STiOCHIOMETRIC * CHEMICAL 1 1 STOICHIOMETRIC * ,- Dl.-PHENYLGL YCINE J PENICILLIN G~ I l_fENICI!-L1~ G -~j RING ENLARGEMENT RING ENLARGEMENT * CHEMICAL DL-PHENYLGL YCINAMIoE-i * CHEMICAL 1 * STOICHIOMETRIC OR ESTER I I* STOICHIOMETRIC r CEPHALOSPClRlN-- - -] KINETIC RESOLUTION [-C;I;PHALOSf>QFUN DEACYLATION * ENZYMATIC OR 1 DEACYLATION * CHEMICAL * ASYMMETRIC * ENZYMATIC 1 I * STOICHIOMETRIC TRANSFORMATION DANE SAL T ADCA . ~~ I -~J D-(-)-PHENYLGL YCINAMIDE [_ADCA----- ACTIVATION J PROTECTION * CHEMICAL * CHEMICAL J * STOICHIOMETRIC * STOICHIOMETRIC ORES~/ L~~~~~YDRID-Cl [pROTECTED -ADCA--l COUPLING I * ENZYMATIC ~~~Al I~--C-E-F-A~L-EX-I-N=--=--_~j I DEPROTECTION I * CHEMICAL r--CEFALEXIN~~ J ADCA = 7-AMINODEACETOXYCEPHALOSPORANIC ACID by eliminating organic waste. The overall production process, however, is more com- plicated, because of several recycle streams and a large number of solids to be handled. A better understanding of enzyme ac- tion on a molecular level and a rational design of improved biocatalysts (includ- ing immobilization) are needed to reach more ideal processes where recycles are eliminated. Also, more adequate down- stream processing including, e.g. selec- tive absorption of end products through modern molecular recognition techniques, are required to achieve feasable processes at plant scale. the 2: I cefalexin-l3-naphthol complex is optimization of all process parameters is obtained [6]. required and extra investments in equip- [I] a.M. Birch, 1.M. Brass, A. Kiener, K. Rob- Again, from a synthetic point of view, ment for handling solids can not be avoid- ins, D. Schmidhalter, N.M. Shaw, T. Zim- an excellent process, but once more the ed. mermann, Chim. Oggi 1995, Sept., 9. chemical engineers have to solve a few [2] S.c. Stinson, Chem. Eng. News 1995, OCI., tough separation and recycle problems: 44. - separation of phenylglycine from the Conclusions [3] A. Bruggink, CPhI Conference Proceedings 1993, p. 38. cefalexin-,B-naphthol complex, [4] A. Bruggink, CPhI Conference Proceedings Integration of biocatalysis in the syn- - isolation of cefalexin, free of I3-naph- 1994, p. 76. thol, from the complex, thesis of s.s. antibiotics, i.e. cefalexin, [5] Patents pending to Chel11ferl11,Gist-hrocades, - isolation and recycling of ,B-naphthol. greatly reduces the number of steps and is DSM Research. All this can be done, but a very careful of considerable benefit to the environment [6] US Pat. 5.470.717..
Load more

Recommended publications
  • Technical Information
    Technical Information Antibiotic Assay Medium No.1 (Seed Agar) Product Code : DM1003 Application: - Antibiotic Assay Medium No.1 (Seed Agar) is used in the microbiological assay of beta-lactam and other antibiotics. Composition** Ingredients Gms / Litre Peptic digest of animal tissue (Peptone) 6.000 or detecting faecal coliforms drinking in water waste water, seawater and foods samples by MPN Method. Casein enzymic hydrolysate 4.000 Yeast extract 3.000 Beef extract 1.500 Dextrose 1.000 Agar 15.000 Final pH (at 25°C) 6.6±0.2 **Formula adjusted, standardized to suit performance parameters Principle & Interpretation The potency of an antibiotic can be determined by chemical, physical and biological methods. An assay is performed to determine the ability of an antibiotic to kill or inhibit the growth of living microorganisms. Biological tests offer the most convenient m eans of performing an assay (1), since a reduction in the antimicrobial activity of a specific antibiotic reveals changes that is not usually displayed by chemical methods (2). Antibacterial susceptibility testing may be performed by either dilution (turbidimetric) or diffusion methods. The choice o f methodology is based on many factors, including ease of performance, flexibility and use of automated or semi-automated devices for both identification and susceptibility testing (3). Grove and Randall have elucidated antibiotic assays and media in their comprehensive treatise on antibiotic assays (4). Antibiotic Assay Medium No.1 is used in the microbiological assay of ß-lactam and other antibiotics. These media are prepared according to the specifications detailed in various pharmacopoeias (2-6) and by the FDA (7).
    [Show full text]
  • – with Novozymes Enzymes for Biocatalysis
    Biocatalysis Pregabalin case study Smarter chemical synthesis – with Novozymes enzymes for biocatalysis The new biocatalytic route results in process improvements, reduced organic solvent usage and substantial reduction of waste streams in Pregabalin production. Introduction Biocatalysis is the application of enzymes to replace chemical Using Lipolase®, a commercially available lipase, rac-2- catalysts in synthetic processes. In recent past, the use of carboxyethyl-3-cyano-5-methylhexanoic acid ethyl ester biocatalysis has gained momentum in the chemical and (1) can be resolved to form (S)-2-carboxyethyl-3-cyano-5- pharmaceutical industries. Today, it’s an important tool for methylhexanoic acid (2). Compared to the first-generation medicinal, process and polymer chemists to develop efficient process, this new route substantially improves process and highly attractive organic synthetic processes on an efficiency by setting the stereocenter early in the synthesis and industrial scale. enabling the facile racemization and reuse of (R)-1. The biocatalytic process for Pregabalin has been developed It outperforms the first-generation manufacturing process also by Pfizer to boost efficiency in Pregabalin production using by delivering higher yields of Pregabalin and by resulting in Novozymes Lipolase®. substantial reductions of waste streams, corresponding to a 5-fold decrease in the E-Factor from 86 to 17. Development of the biocatalytic process for Pregabalin involves four stages: • Screening to identify a suitable enzyme • Performing optimization of the enzymatic reaction to optimize throughput and reduce enzyme loading • Exploring a chemical pathway to preserve the enantiopurity of the material already obtained and lead to Pregabalin, and • Developing a procedure for the racemization of (R)-1 Process improvements thanks to the biocatalytic route Pregabalin chemical synthesis H Knovenagel CN condensation cyanation KOH 0 Et02C CO2Et Et02C CO2Et Et02C CO2Et CNDE (1) CN NH2 1.
    [Show full text]
  • Screening of Macromolecular Cross-Linkers and Food-Grade Additives for Enhancement of Catalytic Performance of MNP-CLEA-Lipase of Hevea Brasiliensis
    IOP Conference Series: Materials Science and Engineering PAPER • OPEN ACCESS Screening of macromolecular cross-linkers and food-grade additives for enhancement of catalytic performance of MNP-CLEA-lipase of hevea brasiliensis To cite this article: Nur Amalin Ab Aziz Al Safi and Faridah Yusof 2020 IOP Conf. Ser.: Mater. Sci. Eng. 932 012019 View the article online for updates and enhancements. This content was downloaded from IP address 170.106.202.226 on 23/09/2021 at 18:45 1st International Conference on Science, Engineering and Technology (ICSET) 2020 IOP Publishing IOP Conf. Series: Materials Science and Engineering 932 (2020) 012019 doi:10.1088/1757-899X/932/1/012019 Screening of macromolecular cross-linkers and food-grade additives for enhancement of catalytic performance of MNP- CLEA-lipase of hevea brasiliensis. Nur Amalin Ab Aziz Al Safi1 and Faridah Yusof1 1 Department of Biotechnology Engineering, International Islamic University Malaysia. Abstract. Skim latex from Hevea brasiliensis (rubber tree) consist of many useful proteins and enzymes that can be utilized to produce value added products for industrial purposes. Lipase recovered from skim latex serum was immobilized via cross-linked enzyme aggregates (CLEA) technology, while supported by magnetic nanoparticles for properties enhancement, termed ‘Magnetic Nanoparticles CLEA-lipase’ (MNP-CLEA-lipase). MNP-CLEA-lipase was prepared by chemical cross-linking of enzyme aggregates with amino functionalized magnetic nanoparticles. Instead of using glutaraldehyde as cross-linking agent, green, non-toxic and renewable macromolecular cross-linkers (dextran, chitosan, gum Arabic and pectin) were screened and the best alternative based on highest residual activity was chosen for further analysis.
    [Show full text]
  • Contractor Orientation Manual
    Contractor Orientation Manual KALAMAZOO CONTRACTOR ADMINISTRATION TABLE OF CONTENTS INTRODUCTION......................................................................................................................................4 DEFINITIONS...........................................................................................................................................4 1. Supplier: ........................................................................................................................................4 2. Contractor: ………………………………………………………………………………………4 3. Pfizer Contact: ...…………………………………………………………………………….4 4. Kalamazoo Contractor Administration: ……………………………………………………..4 GENERAL INFORMATION....................................................................................................................5 1. Company Access ...........................................................................................................................5 2. Vehicle Admittance & Parking .....................................................................................................5 3. Tobacco Products ..........................................................................................................................6 4. Cafeterias and Snack Bars..............................................................................................................6 5. The Federal Food, Drug and Cosmetic Act................................................................................... 6 6. Good Manufacturing Practices
    [Show full text]
  • Custom Manufacturing in Thailand, Evonik in China
    10/2011 October Markets and Companies Markets and Companies Interview with Styrolution’s CEO THE NEWSPAPER FOR THE Expert Peter Pollak discusses the Roberto Gualdoni CHEMICAL AND fragmented world of fine chemicals Page 5 LIFE SCIENCE MARKE TS Pages 8 and 14 N EWSFLOW Market and Companies: Haltermann sold to H.I.G Europe, Dr. Uwe Nickel named new CEO. An Industry Full of Opportunity DuPont seeking buyers for two se- parate businesses: a polyester-film CPhI Highlights the Latest Trends in Pharma joint venture and one that makes powder-based paint. Bayer and Yunona Holdings have entered a memorandum of under- Markus Blocher Dr. Jörn Winterfeld standing to manufacture drugs in CEO, Dottikon Russia. Director Business Line Pharma/Agro at Wacker Biosolutions, Wacker AstraZeneca has announced it will be laying off about 400 employees in the U.S., primarily at its head- API Fine Chemicals quarters in Wilmington, Del. … Chemical exclusive synthesis partners Consolidation in the fine chemicals industry Lanxess has announced three in- need to possess a versatile technology will continue, since it is a very fragmented vestments totaling upwards of €30 “ portfolio like a Swiss army knife and be as industry. Many small players may vanish million in Brazil. ” “ ” precise and reliable as a Swiss watch. or merge to attain the so-called critical mass. Syngenta has posted a 21 % rise in This trend includes producers in China. its Q3 results over last year. More on Page 2 ▶ Jean Bléhaut Director of Marketing & Business Development, Novasep Dr. Martin Wienkenhöver Under Construction: CEO, CABB Both Solvay and Evonik are building hydrogen peroxide plants; Solvay Custom Manufacturing in Thailand, Evonik in China.
    [Show full text]
  • Evolution of a Regulatory Framework for Pharmaceuticals Derived from Genetically Modified Plants
    Review Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants Armin Spo¨k1*, Richard M. Twyman2, Rainer Fischer3, Julian K.C. Ma4 and Penelope A.C. Sparrow5* 1 Inter-University Research Centre for Technology, Work and Culture (IFZ), Schlo¨ gelgasse 2, A-8010 Graz, Austria 2 Department of Biology, University of York, Heslington, York, YO10 5DD, UK 3 Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Aachen, Germany 4 St George’s Hospital Medical School, Cranmer Terrace, London, SW17 0RE, UK 5 John Innes Centre, Norwich Research Park, Norwich, NR4 7UH, UK The use of genetically modified (GM) plants to synthes- phase II clinical trials, respectively [6]. In 2006, the United ize proteins that are subsequently processed, regulated States Department of Agriculture (USDA) licensed a poul- and sold as pharmaceuticals challenges two very differ- try vaccine produced in cultured tobacco cells [7]. Since ent established regulatory frameworks, one concerning then, several products derived from crop plants have also GM plants and the other covering the development of reached late development stages, including human insulin biotechnology-derived drugs. Within these regulatory and carp growth hormone produced in safflower. These are systems, specific regulations and guidelines for plant- expected to reach the market between 2008 and 2010 (see made pharmaceuticals (PMPs) – also referred to as plant- Table 1). derived pharmaceuticals (PDPs) – are still evolving. The PMPs present two major challenges for the regulatory products nearing commercial viability will ultimately bodies. Regulators of agricultural biotechnology are con- help to road test and fine-tune these regulations, and fronted with a novel type of crop use, and drug regulators might help to reduce regulatory uncertainties.
    [Show full text]
  • New Deals, New Investments in Chemical Manufacture
    Chemical Manufacture New deals, new investments in chemical manufacture We review some of the most recent contracts, investments and merger and acquisition activities in the highly competitive field of fine chemical manufacture. he manufacture of pharmaceutical fine chemical business is a major player in the global fine chemical sector, intermediates and ingredients remains probably the with a leading position in the supply of contract manufacturing Tmost competitive sector of the chemical industry and services to the agrochemicals, pharmaceutical and speciality there continue to be major changes in the structure of the chemical industries. The acquisition included all Avecia Fine sector and in the geographical spread of major manufacturing Chemicals’ assets and operations on the 65 hectare site at faciltiies, with investments in China and India playing a leading Grangemouth, UK. All 310 Avecia Fine Chemicals’ employees part in companies’ moves to acquire stronger positions. This were included in the transaction. In 2004, the business article looks at just a few of the recent developments. recorded sales of £38 million. Avecia Fine Chemicals Limited now operates as KemFine UK Acquisition of ozone chemistry technology Ltd. Tom Shields is the managing director, and is based at the In February, Dishman Pharmaceuticals & Chemicals Ltd Grangemouth site. KemFine, previously Kemira Fine Chemicals acquired IO3S Ltd of Bern, Switzerland, through its 100% Oy, was created via an MBO of the business from Kemira in wholly owned Switzerland based subsidiary company M/s. 2004. 3i, a world leader in the private equity and venture Dishman Switzerland Ltd. The Assets base of IO3S is currently capital sector, supported the management team in the about $2 million but Dishman says the acquisition was transaction and in the equity funding.
    [Show full text]
  • Chemacx Vendor List
    ChemACX Vendor List -A B C D E F G H I J K L M N O P Q R S T U V W X Y Z- -#- APAC PHARMACEUTICAL ACTIVATE SCIENTIFIC GMBH AQCHEM LLC ADESIS INC. 1K SCIENTIFIC ASW MEDCHEM, INC. ADVAMACS 3A PHARMATECH AURUM PHARMATECH LLC ADVANCE RESEARCH CHEMICALS, INC. 3B SCIENTIFIC CORP. AARON CHEMISTRY ADVANCED AROMATICS, L.P. 3RCHEM ABAMACHEM LTD ADVANCED ASYMMETRICS, INC. 8S LABORATORIES LLC ABBEY COLOR ADVANCED CHEMBLOCKS INC. Updated Aug. 2018 -A- ABBOTT LABORATORIES CHEMICAL DIVISION ADVANCED CHEMTECH A&A LIFE SCIENCE INC. DBA ABBY PHARMATECH LLC ADVANCED MOLECULAR AVACHEM SCIENTIFICS TECHNOLOGIES PTY LTD ABERJONA LABORATORIES A&C PHARMTECH, INC ADVANCED SCIENTIFIC ABOVCHEM LLC INTERNATIONAL, LLC A&J PHARMATECH ABSOLUTE CHIRAL ADVANCED SYNTHESIS A.G. SCIENTIFIC Updated July 2018 TECHNOLOGIES, S.A. Updated Jan. 2018 ACADECHEM COMPANY LIMITED ADVANCED TECHNOLOGY & A1 BIOCHEM LABS INDUSTRIAL CO., LTD. Updated Sep. 2018 ACADEMIQUE PHYTOCANADA AIMS FINE CHEMICALS INC. AA BLOCKS LLC ACCELA CHEMBIO CO., LTD. New Sep. 2018 Updated June 2018 AIR PRODUCTS & CHEMICALS, INC. AB CHEM TECHNOLOGIES LLC ACCELEDEV CHEMICAL LLC AJINOMOTO - AMINO ACID DEPARTMENT ABCR GMBH & CO. KG ACCUSTANDARD, INC. ALBANY MOLECULAR RESEARCH, INC. ABSCO LTD ACE SYNTHESIS LLC ALBEMARLE CORPORATION ABX ADVANCED BIOCHEMICAL ACENTEX SCIENTIFIC, INC. COMPOUNDS ALBRIGHT & WILSON AMERICAS ACESYS PHARMATECH AECHEM ALCHEM INTERNATIONAL LIMITED ACETO CORPORATION AK SCIENTIFIC, INC. ALCHEM PHARMTECH, INC. Updated Sep. 2018 ACHEMICA ALDLAB CHEMICALS, LLC AKL RESEARCH LLP ACINOPEPTIDE CO. LTD ALDRICH AOBCHEM USA ACME BIOSCIENCE, INC. ALFA AESAR AOKBIO CO., LTD ACROS ORGANICS Updated Apr. 2018 ALFA CHEMISTRY ACROS ORGANICS – USA New June 2018 AOKCHEM CO., LTD.
    [Show full text]
  • A Fine Art How Much of the Fin E Chemicals Market Can Pharma Lay Claim to Today- and in the Future? Jan Ramakers, Jan Ramakers Fine Chemical Consulting Group Writes
    E CHEMICALS • A fine art How much of the fin e chemicals market can pharma lay claim to today- and in the future? Jan Ramakers, Jan Ramakers Fine Chemical Consulting Group writes ine chemicals, speciality chemicals, and performance chemicals are some of the various names used to describe products in the Fine chemical market in 2014 Fhigh-value end of the chemical market. In order to avoid any - total value $127.7bn - confusion, it is good to keep in mind that fine chemicals ore defined as (high value) chemical products that ore sold for what they ore, ie for Other Pharma their precise chemical structure. Speciality chemicals, often also referred Food a to as performance chemicals, are (high value) chemical products that 4% ore sold for what they do. So an intermediate used in the manufacture Pigments& of a specific API is a fine chemical as it needs to have a very specific 3% chemical structure; a different chemical structure cannot be used. Fine chemicals are used across a wide range of market segments, and it is easy enough to make a list that features 40-50 different application intermediates areas. 10% The products end up in speciality chemicals markets, for instance as Fragrances active ingredients in biocide formulations, as additives for plastics and 7% coatings, or as active ingredients in cosmetics and toiletries. Some are Figure 1. used as intermediates in the manufacture of liquid crystal displays, and so on. Many of those end markets are quite large, but most of them are fairly small as an outlet for fine chemicals.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2007/0122887 A1 Klopprogge Et Al
    US 2007.0122887A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0122887 A1 Klopprogge et al. (43) Pub. Date: May 31, 2007 (54) GENE VARIANTS CODING FOR PROTEINS (30) Foreign Application Priority Data FROM THE METABOLIC PATHWAY OF FNE CHEMICALS Dec. 18, 2003 (DE)..................................... 103 59 661.5 (75) Inventors: Corinna Klopprogge, Mannheim (DE); Publication Classification Oskar Zelder, Speyer (DE); Burkhard Kroger, Limburgerhof (DE); Hartwig (51) Int. Cl. Schroder, Nublock (DE); Stefan CI2P I3/04 (2006.01) Haefner, Ludwigshafen (DE); Uwe CI2P I3/08 (2006.01) Ruffer, Meckenheim (DE); Claudia C7H 2L/04 (2006.01) Isabella Graef, Lampertheim (DE) CI2N 9/10 (2006.01) CI2N 15/74 (2006.01) Correspondence Address: CI2N I/2 (2006.01) LAHIVE & COCKFIELD, LLP ONE POST OFFICE SQUARE (52) U.S. Cl. ......................... 435/106; 435/115; 435/193; BOSTON, MA 02109-2127 (US) 435/252.3; 435/471; 536/23.2 (73) Assignee: BASF Aktiengesellschaft, Ludwigshafen (DE) (57) ABSTRACT (21) Appl. No.: 10/583,404 (22) PCT Filed: Dec. 16, 2004 The present invention relates to mutated nucleic acids and proteins of the metabolic pathway of fine chemicals, to (86). PCT No.: PCT/EPO4/14338 processes for preparing genetically modified producer organisms, to processes for preparing fine chemicals by S 371(c)(1), culturing said genetically modified organisms and to said (2), (4) Date: Jun. 16, 2006 genetically modified organisms themselves. US 2007/O 122887 A1 May 31, 2007 GENEVARLANTS CODNG FOR PROTEINS FROM and optimized C yield, there is a constant need for further THE METABOLIC PATHWAY OF FINE improving the productivity of said organisms.
    [Show full text]
  • Fine Chemical Intermediates
    Fine Chemical Intermediates On Request (OR) / Main Structure Identification Characteristics Regular Applications Production (RP) Phosgene derivatives Methyl chloroformate Assay: min. 99% by area Organic reagent for RP O MCF, Methyl chlorocarbo- introduction of the nate, Chloroformic acid Appearance: colourless to methoxycarbonyl methyl ester pale yellow liquid group, synthesis of Packaging: 160 kg drum, carbonates, Cl O CAS Reg. No. 79-22-1 ISO tank carbamates, anhydrides etc. Ethyl chloroformate Assay: min. 98.5% by area Organic reagent for RP O ECF, Ethyl introduction of the chlorocarbonate, Appearance: colourless to ethoxycarbonyl group, Chloroformic acid ethyl pale yellow liquid synthesis of ester Packaging: 160 kg drum, carbonates, Cl O ISO tank carbamates, CAS Reg. No. 541-41-3 anhydrides etc. n-Propyl chloroformate Assay: min. 98% by area Organic reagent for OR O nPCF, n-Propyl chlorocar- introduction of the n- bonate, Chloroformic acid Appearance: colourless to propoxycarbonyl propyl ester pale yellow liquid group, synthesis of Cl O Packaging: ISO tank carbonates, CAS Reg. No. 109-61-5 carbamates, anhydrides etc. Isopropyl chloroformate Assay: min. 98.5% by area Organic reagent for OR O iPCF, 2- introduction of the Propylchloroformate, Appearance: clear colour- isopropoxycarbonyl Chloroformic acid less to pale yellow liquid group, synthesis of isopropyl ester Packaging: ISO tank carbonates, Cl O carbamates, CAS Reg. No. 108-23-6 anhydrides etc. n-Pentylchloroformate Assay: min. 98.5% by area Organic reagent for OR n-Pentylchlorocarbonate, introduction of the n- O Chloroformic acid pentyl Appearance: colourless pentoxycarbonyl ester liquid group, synthesis of Packaging: 190 kg drum carbonates, Cl O CAS Reg. No. 638-41-5 carbamates, anhydrides etc.
    [Show full text]
  • Chapter 2 Immobilization of Enzymes
    Chapter 2 Immobilization of Enzymes: A Literature Survey Beatriz Brena , Paula González-Pombo , and Francisco Batista-Viera Abstract The term immobilized enzymes refers to “enzymes physically confi ned or localized in a certain defi ned region of space with retention of their catalytic activities, and which can be used repeatedly and continuously.” Immobilized enzymes are currently the subject of considerable interest because of their advantages over soluble enzymes. In addition to their use in industrial processes, the immobilization techniques are the basis for making a number of biotechnology products with application in diagnostics, bioaffi nity chromatography, and biosensors. At the beginning, only immobilized single enzymes were used, after 1970s more complex systems including two-enzyme reactions with cofactor regeneration and living cells were developed. The enzymes can be attached to the support by interactions ranging from reversible physical adsorp- tion and ionic linkages to stable covalent bonds. Although the choice of the most appropriate immobilization technique depends on the nature of the enzyme and the carrier, in the last years the immobilization tech- nology has increasingly become a matter of rational design. As a consequence of enzyme immobilization, some properties such as catalytic activity or thermal stability become altered. These effects have been demonstrated and exploited. The concept of stabilization has been an important driving force for immobilizing enzymes. Moreover, true stabilization at the molecular level has been demonstrated, e.g., proteins immobilized through multipoint covalent binding. Key words Immobilized enzymes , Bioaffi nity chromatography , Biosensors , Enzyme stabilization , Immobilization methods 1 Background Enzymes are biological catalysts that promote the transformation of chemical species in living systems.
    [Show full text]